Investigational drug · Phase 3
Encaleret
Also called: CLTX-305
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Autosomal Dominant Hypocalcemia Type 1 (ADH1), Autosomal Dominant Hypocalcemia (ADH), Hypoparathyroidism.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "Encaleret"
First trial start
2023
Jan 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Encaleret", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Autosomal Dominant Hypocalcemia (ADH)
- Hypoparathyroidism
- Chronic Hypoparathyroidism
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Encaleret" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismPivotal-lookingRecruiting
Calcilytix Therapeutics, Inc., a BridgeBio companyIndustry
NCT07805356 · 160 participants (planned) · Start Aug 31, 2026 · Primary completion Jan 2028
Drug: Encaleret; Placebo · For: Hypoparathyroidism; Chronic Hypoparathyroidism
Sites: Indianapolis, Indiana; Boston, Massachusetts; Reno, Nevada · 10 sites in all
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Pivotal-lookingActive, not recruiting
Calcilytix Therapeutics, Inc., a BridgeBio companyIndustry
NCT05680818 · 67 participants · Start Jan 6, 2023 · Primary completion Aug 22, 2025
Drug: Encaleret · For: Autosomal Dominant Hypocalcemia (ADH)
Sites: Oakland, California; Aurora, Colorado; Indianapolis, Indiana · 25 sites in all
- Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Pivotal-lookingRecruiting
Calcilytix Therapeutics, Inc., a BridgeBio companyIndustry
NCT07080385 · 28 participants (planned) · Start Jan 30, 2026 · Primary completion Dec 2028
Drug: Encaleret · For: Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Jacksonville, Florida · 6 sites in all
- PTH-independent Effects of EncaleretCompleted
National Institute of Dental and Craniofacial Research (NIDCR)NIH
NCT05735015 · 13 participants · Start Sep 1, 2023 · Primary completion May 21, 2025
Drug: encaleret · For: Post-Surgical Hypoparathyroidism
Sites: Bethesda, Maryland
Calcilytix Therapeutics, Inc., a BridgeBio companyIndustry
NCT04581629 · 13 participants · Start Sep 20, 2020 · Primary completion Sep 7, 2023
Drug: Encaleret · For: Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Hypoparathyroidism: translating science from the laboratory to the clinic.
Brandi ML, AbuAlrob H, Chang W, et al. · Lancet Diabetes Endocrinol 2026
- PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial.
Hartley IR, Gafni RI, Li X, et al. · Res Sq 2026
- Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.
Rejnmark L · Endocrinol Metab (Seoul) 2024
- Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1.
Gafni RI, Hartley IR, Roszko KL, et al. · N Engl J Med 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.